{"id":"https://genegraph.clinicalgenome.org/r/121abaca-b43e-45d2-905e-61d6a702c151v1.0","type":"EvidenceStrengthAssertion","dc:description":"Variants in the *GRN* gene have been reported in relation to both autosomal dominant frontotemporal dementia and autosomal recessive neuronal ceroid lipofuscinosis (NCL) (PMID: 16862116, 16862115, 22608501). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found differences in inheritance pattern and phenotypic variability for these assertions. Therefore, these assertions have been split into the following disease entities: autosomal dominant Amyotrophic lateral Sclerosis (ALS) and/or Frontotemporal dementia (FTD) and autosomal recessive neuronal ceroid lipofuscinosis (NCL). This curation for autosomal dominant ALS,  ALS-FTD and FTD does not include probands from autosomal recessive neuronal ceroid lipofuscinosis\nHeterozygous loss of function variants (frameshift or nonsense) in the *GRN* gene have been commonly reported in individuals with FTD, however occasionally, missense variants seen in signal sequence or initiator codon result in low or absent PGRN protein, consistent with a loss-of-function mechanism of disease (PMIDs: 17436289, 18184915, 23596077, 32772750, 17436289, 18184915, 23596077, 32772750, 16862116, 16862115, 17436289, 18183624). In all instances of literature when available, affected probands with *GRN* variants are identified to have low or absent PGRN consistent with a loss of function mechanism of disease – including the missense variant p.Ala9Asp. With the genetic evidence available in the literature, the score for genetic evidence for the ALS, ALS-FTD cases is 2.1, this is combined with the pure FTD cases to reach the maximum score for genetic evidence reached (12 points). It is emphasized that most of the evidence is from FTD but there are a handful of cases with MND phenotype. Evidence supporting this gene disease pair also includes experimental data from human cell lines and patient fibroblasts showing low expression of PGRN protein in addition to haploinsufficient FTD mouse model  (PMID: 17984093, 29874572, 23063362, 23516300). \nIn summary, *GRN* is definitively associated with autosomal dominant frontotemporal dementia and/or amyotrophic lateral sclerosis. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/121abaca-b43e-45d2-905e-61d6a702c151","GCISnapshot":"https://genegraph.clinicalgenome.org/r/e76545e6-2411-44c5-a458-99f02aa7ff44","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/e76545e6-2411-44c5-a458-99f02aa7ff44_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2023-05-25T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/e76545e6-2411-44c5-a458-99f02aa7ff44_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2023-06-13T18:50:57.981Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e76545e6-2411-44c5-a458-99f02aa7ff44_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e7c83d2-0560-41e8-8342-42199d06f4e4","type":"EvidenceLine","dc:description":"Highly conserved granular domain. SIFT analysis predicted that Arg418Gln is unlikely to affect protein function","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e7c83d2-0560-41e8-8342-42199d06f4e4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18184915","allele":{"id":"https://genegraph.clinicalgenome.org/r/d900fda3-a5f6-4e4a-a092-08ac721217cc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.1253G>A (p.Arg418Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225330"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/657f739d-067d-48a3-a3ea-8db3d60866a0","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/657f739d-067d-48a3-a3ea-8db3d60866a0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Disruption of SRP (Signal recognition particle) recruitment triggers GRN mRNA degradation\n(SRP recruitment is important for mRNA stability). A9D cannot recruit SRP efficiently.\nA9D signal sequence is sufficient to trigger mRNA degradation (Pinarbasi ES, et al.,\n2018, PMID: 29874572)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/657f739d-067d-48a3-a3ea-8db3d60866a0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23596077","allele":{"id":"https://genegraph.clinicalgenome.org/r/9eff19d6-c37e-4b34-913e-6ef90ce4a89d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.26C>A (p.Ala9Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225199"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a992564a-6e25-435f-9ce9-646b6c1d8af6","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a992564a-6e25-435f-9ce9-646b6c1d8af6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18183624","allele":{"id":"https://genegraph.clinicalgenome.org/r/ab5f9b1a-5704-4c2e-a9b0-b7cc4fe7946c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.709-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225270"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e76545e6-2411-44c5-a458-99f02aa7ff44_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5fe932ba-0ba3-482a-8800-8fba3e25aad8_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862115","rdfs:label":"DR8","family":{"id":"https://genegraph.clinicalgenome.org/r/5fe932ba-0ba3-482a-8800-8fba3e25aad8","type":"Family","rdfs:label":"DR8","member":{"id":"https://genegraph.clinicalgenome.org/r/2fc34224-9643-4595-bcef-cce701a17563","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862115","rdfs:label":"DR8-III-28","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":62,"allele":{"id":"https://genegraph.clinicalgenome.org/r/1801c28d-f551-4b28-bbe1-af3ecdbaef33","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.-8+5G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225192"}},"firstTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b0bed48f-10c2-46fc-89b8-c78e9476164e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862115","allele":{"id":"https://genegraph.clinicalgenome.org/r/1801c28d-f551-4b28-bbe1-af3ecdbaef33"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":8,"phenotypes":"obo:HP_0002145","proband":{"id":"https://genegraph.clinicalgenome.org/r/2fc34224-9643-4595-bcef-cce701a17563"}},{"id":"https://genegraph.clinicalgenome.org/r/189b8d07-eb5f-45e3-88f3-64d7b82913bf_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16950801","rdfs:label":"FD1","family":{"id":"https://genegraph.clinicalgenome.org/r/189b8d07-eb5f-45e3-88f3-64d7b82913bf","type":"Family","rdfs:label":"FD1"},"phenotype":{"id":"obo:HP_0002145"},"phenotypePositiveAllelePositive":12},{"id":"https://genegraph.clinicalgenome.org/r/fdd511d8-7d5a-4dee-9bf6-d4daa672177a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862116","rdfs:label":"UBC-15 ","family":{"id":"https://genegraph.clinicalgenome.org/r/fdd511d8-7d5a-4dee-9bf6-d4daa672177a","type":"Family","rdfs:label":"UBC-15 ","member":{"id":"https://genegraph.clinicalgenome.org/r/41e315e2-3ab7-4f05-82e3-10819c59df55","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862116","rdfs:label":"UBC-15-1","allele":{"id":"https://genegraph.clinicalgenome.org/r/31bf6088-1cbd-4ef3-a216-d18e3007d876","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.1252C>T (p.Arg418Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225327"}},"firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0002145","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/15203676-641a-4222-8867-2b7cdd76d20b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862116","allele":{"id":"https://genegraph.clinicalgenome.org/r/31bf6088-1cbd-4ef3-a216-d18e3007d876"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":1,"phenotypes":"obo:HP_0002145","proband":{"id":"https://genegraph.clinicalgenome.org/r/41e315e2-3ab7-4f05-82e3-10819c59df55"}},{"id":"https://genegraph.clinicalgenome.org/r/24302387-ddd8-4034-bafc-f8a13d60b23c_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17436289","rdfs:label":"F171","family":{"id":"https://genegraph.clinicalgenome.org/r/24302387-ddd8-4034-bafc-f8a13d60b23c","type":"Family","rdfs:label":"F171","member":{"id":"https://genegraph.clinicalgenome.org/r/dcfd5a8a-6d70-498b-9814-ed429e1ea710","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17436289","rdfs:label":"F171-001","allele":{"id":"https://genegraph.clinicalgenome.org/r/813d1e8f-dc4f-4fff-858d-8efe1dfbcc3f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.1201C>T (p.Gln401Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225319"}},"firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0002145","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/984cef17-73a5-484b-9d70-22f02c4b4811_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17436289","allele":{"id":"https://genegraph.clinicalgenome.org/r/813d1e8f-dc4f-4fff-858d-8efe1dfbcc3f"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":6,"phenotypes":"obo:HP_0002145","proband":{"id":"https://genegraph.clinicalgenome.org/r/dcfd5a8a-6d70-498b-9814-ed429e1ea710"}},{"id":"https://genegraph.clinicalgenome.org/r/9e95a136-fa0b-4841-9760-bc0fc00357e0_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862116","rdfs:label":"UBC-17","family":{"id":"https://genegraph.clinicalgenome.org/r/9e95a136-fa0b-4841-9760-bc0fc00357e0","type":"Family","rdfs:label":"UBC-17","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/f8d2befe-2dd9-42e6-9819-3ea71b3dbbb2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862116","rdfs:label":"UBC-17-1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":65,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d9f9f665-f344-4362-b423-8732b54985bf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.87_90dup (p.Cys31LeufsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225205"}},"detectionMethod":"Detailed information in paper- MacKenzie et al, PMID: 16401619 ","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f20f6100-27bd-4add-b3b0-3f51fa510a63_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862116","allele":{"id":"https://genegraph.clinicalgenome.org/r/d9f9f665-f344-4362-b423-8732b54985bf"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":8,"phenotypes":"obo:HP_0002145","proband":{"id":"https://genegraph.clinicalgenome.org/r/f8d2befe-2dd9-42e6-9819-3ea71b3dbbb2"},"publishedLodScore":3.65},{"id":"https://genegraph.clinicalgenome.org/r/53de0956-2ea3-4470-8123-755b52a377a8_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862115","rdfs:label":"1083","family":{"id":"https://genegraph.clinicalgenome.org/r/53de0956-2ea3-4470-8123-755b52a377a8","type":"Family","rdfs:label":"1083","member":{"id":"https://genegraph.clinicalgenome.org/r/5d198e43-4c25-4c30-9cc8-7671e27011a9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862115","rdfs:label":"III-30","allele":{"id":"https://genegraph.clinicalgenome.org/r/9fc8d093-40d4-4a13-aa5c-6668ce94be2a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.373C>T (p.Gln125Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225238"}},"firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0002145","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3a90e9bb-dd3c-4ecf-b527-4ad1f446665c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16862115","allele":{"id":"https://genegraph.clinicalgenome.org/r/9fc8d093-40d4-4a13-aa5c-6668ce94be2a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":15,"phenotypes":"obo:HP_0002145","proband":{"id":"https://genegraph.clinicalgenome.org/r/5d198e43-4c25-4c30-9cc8-7671e27011a9"}},{"id":"https://genegraph.clinicalgenome.org/r/0b0b8972-f4f2-4a7a-bd4f-adb8ed4becd5_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18183624","rdfs:label":"FD1","family":{"id":"https://genegraph.clinicalgenome.org/r/0b0b8972-f4f2-4a7a-bd4f-adb8ed4becd5","type":"Family","rdfs:label":"FD1","member":{"id":"https://genegraph.clinicalgenome.org/r/ee7cad51-7aa0-4433-8060-b1c0d40067ca","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18183624","rdfs:label":"FD1-3:7","allele":{"id":"https://genegraph.clinicalgenome.org/r/ab5f9b1a-5704-4c2e-a9b0-b7cc4fe7946c"},"firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0002145","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/a992564a-6e25-435f-9ce9-646b6c1d8af6_variant_evidence_item"}}},"phenotypePositiveAllelePositive":12,"phenotypes":"obo:HP_0002145","proband":{"id":"https://genegraph.clinicalgenome.org/r/ee7cad51-7aa0-4433-8060-b1c0d40067ca"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/3a90e9bb-dd3c-4ecf-b527-4ad1f446665c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a90e9bb-dd3c-4ecf-b527-4ad1f446665c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transcript and protein analyses demonstrate that the PGRN carrier does not produce the protein.\nNormalized PGRN staining in lymphoblasts of Gln125X carriers was reduced by 30–35% compared to unaffected relatives\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3a90e9bb-dd3c-4ecf-b527-4ad1f446665c_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a8ce5c85-faf6-4ee5-b2d1-3b691bcbb10c","type":"EvidenceLine","dc:description":"limb-onset sporadic ALS c.764C>T (p.The182Met) (gnomAD = MAF = 0.002806","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8ce5c85-faf6-4ee5-b2d1-3b691bcbb10c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17371905","allele":{"id":"https://genegraph.clinicalgenome.org/r/3b3a1d37-8f4b-4bf5-a51b-e691fe40d565","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.545C>T (p.Thr182Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225254"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/973fe5ed-fd8e-44be-9091-f710d7b3d5c6","type":"EvidenceLine","dc:description":"ALS-FTD patient c.578C>A (p.Ser120Tyr) (gnomAD = MAF =0.0008536)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/973fe5ed-fd8e-44be-9091-f710d7b3d5c6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17371905","allele":{"id":"https://genegraph.clinicalgenome.org/r/009b3f34-97ae-40ae-a255-72f1cf73c203","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.359C>A (p.Ser120Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225234"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/984cef17-73a5-484b-9d70-22f02c4b4811","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/984cef17-73a5-484b-9d70-22f02c4b4811_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f20f6100-27bd-4add-b3b0-3f51fa510a63","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f20f6100-27bd-4add-b3b0-3f51fa510a63_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant PGRN mRNAs with premature termination codons are degraded by nonsense-mediated decay.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/f20f6100-27bd-4add-b3b0-3f51fa510a63_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/15203676-641a-4222-8867-2b7cdd76d20b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15203676-641a-4222-8867-2b7cdd76d20b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Quantitative PCR with reverse transcription (qRT–PCR) on RNA extracted from patient lymphoblasts carrying the R418X (UBC15) and C31LfsX34 (UBC17) mutations showed that both were associated with a ∼50% reduction in total PGRNmRNA relative to lymphoblasts from unaffected individuals \nwestern blot analysis showed that wild-type PGRN protein was reduced in extracts from R418X and C31LfsX34 lymphoblasts \n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/15203676-641a-4222-8867-2b7cdd76d20b_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/054935c7-4ba2-4ee7-8a7e-f340811cc60d","type":"EvidenceLine","dc:description":"Highly conserved granular domain. SIFT analysis predicted that AL324Thr is unlikely to affect protein function","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/054935c7-4ba2-4ee7-8a7e-f340811cc60d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18184915","allele":{"id":"https://genegraph.clinicalgenome.org/r/6c8b6db7-9e75-466d-8479-d10b43b0688a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.970G>A (p.Ala324Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA225301"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/0fd1fa59-da9b-4fb6-a0d0-825688bef6a4","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0fd1fa59-da9b-4fb6-a0d0-825688bef6a4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18184915","allele":{"id":"https://genegraph.clinicalgenome.org/r/a5841098-1bc7-48d7-9557-be54b002baac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.371T>C (p.Ile124Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399762661"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/b0bed48f-10c2-46fc-89b8-c78e9476164e","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b0bed48f-10c2-46fc-89b8-c78e9476164e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Normalized PGRN staining in lymphoblasts of IVS0 + 5G > C acarriers was reduced by 30–35% compared to unaffected relatives\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b0bed48f-10c2-46fc-89b8-c78e9476164e_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/b37d343b-092d-43fa-86f8-14d29170e8d8","type":"EvidenceLine","dc:description":"The NEK1 gene is associated with ALS which could be the explanation of the disease in this patient","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b37d343b-092d-43fa-86f8-14d29170e8d8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32772750","allele":{"id":"https://genegraph.clinicalgenome.org/r/b9273bf2-b73b-420f-bf8e-d5e80c5ff3fd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.415T>C (p.Cys139Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8601879"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/a92eed7f-4731-4266-b765-c387f602c668","type":"EvidenceLine","dc:description":"Highly conserved residue at the end of the granulin domain. SIFT analysis predicted that Arg110Gln were unlikely to affect protein function","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a92eed7f-4731-4266-b765-c387f602c668_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18184915","allele":{"id":"https://genegraph.clinicalgenome.org/r/1f4bbbff-dfc5-403f-9c43-c8e074a5f51c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002087.4(GRN):c.329G>A (p.Arg110Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8601839"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/e76545e6-2411-44c5-a458-99f02aa7ff44_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e76545e6-2411-44c5-a458-99f02aa7ff44_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b0ae0e4f-1b3c-4069-9117-a7b3d2f1dfbf","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e6a9d23-c193-47b1-9b4c-845d6083f174","type":"Finding","dc:description":"Patients with FTD experience incapacitating behavioral changes, which commonly include social withdrawal and emotional blunting (Rascovsky et al., 2011). These symptoms result from dysfunction of a brain network called the salience network, which includes the amygdala, anterior cingulate cortex, insular cortex, limbic ventral striatum, and other regions (Seeley et al., 2009; Zhou et al., 2010). ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23516300","rdfs:label":"Progranulin Haploinsufficient Mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e76545e6-2411-44c5-a458-99f02aa7ff44_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2584cd12-7824-425c-acab-aac2e012b380","type":"EvidenceLine","dc:description":"Already added in the genetic evidence. (Disruption of SRP (Signal recognition particle) recruitment triggers GRN mRNA degradation (SRP recruitment is important for mRNA stability). A9D cannot recruit SRP efficiently. A9D signal sequence is sufficient to trigger mRNA degradation)","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/87054f73-88ee-4ac5-8d95-3e0cd07528e1","type":"FunctionalAlteration","dc:description":"A9D mRNA is specifically degraded in patient-derived cells, and mRNA degradation is translation dependent\nDisruption of SRP (Signal recognition particle) recruitment triggers GRN mRNA degradation (SRP recruitment is important for mRNA stability). A9D cannot recruit SRP efficiently. A9D signal sequence is sufficient to trigger mRNA degradation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29874572","rdfs:label":"A9D GRN mRNA Levels Are Decre ased Relative to WT GRN and V5"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/6750f2a9-ab9e-4b91-aee6-64661f6a324b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c22df4ac-78cb-4e6b-9189-156f711b0bd0","type":"FunctionalAlteration","dc:description":"Progranulin mutation located within the signal sequence (PGRN A9D) results in cytoplasmic missorting with extremely low expression. In contrast, two other progranulin mutations (PGRN P248L and R432C) are expressed as immature proteins but are inefficiently transported through and partially degraded within the secretory pathway, resulting in a significantly reduced secretion.\nAlso, Taken together with the biochemical analysis, these data demonstrate that wt and mutant PGRN and TDP-43 are not co-expressed in any subcellular compartment excluding a direct interaction. Moreover, at least in the background of endogenous PGRN, the PGRN mutants do not affect the nuclear localization of TDP-43.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17984093","rdfs:label":"HeLa cells transfected with wt PGRN, A9D, P2 48L, R432C"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1f020046-8d6d-414e-806e-1ca7d950758d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e9a8bf13-a567-4b8b-8415-f18d0e2e6fc8","type":"FunctionalAlteration","dc:description":"Generated multiple induced pluripotent stem cell lines from a control subject, a patient with sporadic FTD, and an FTD patient with a novel heterozygous GRN mutation (progranulin [PGRN] S116X)\nPGRN S116X induced pluripotent stem cells, the levels of intracellular and secreted PGRN were reduced, establishing patient-specific cellular models of PGRN haploinsufficiency\nIn cells from the FTD patient with the PGRN S116X mutation, the mRNA level was only about 30% of controls consistent with the substantially lower average plasma progranulin levels in FTD patients harboring GRN mutations than in those without such mutations (Coppola et al., 2008; Finch et al., 2009)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23063362","rdfs:label":"FTD Patient-Specific Neuronal Model-GRN haploinsufficiency "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3}],"evidenceStrength":"Definitive","sequence":6401,"specifiedBy":"GeneValidityCriteria9","strengthScore":15,"subject":{"id":"https://genegraph.clinicalgenome.org/r/I_EMYPJnrYo","type":"GeneValidityProposition","disease":"obo:MONDO_0030923","gene":"hgnc:4601","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_e76545e6-2411-44c5-a458-99f02aa7ff44-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}